COPENHAGEN, 30 August 2022 — In keeping with the foundation’s benevolent goals, the Bill & Melinda Gates Foundation has pledged to spend USD 5 million to help Bactolife’s technology platform expedite the development of Binding Proteins, a revolutionary biologic strategy to lower the risk of gut infections in both humans and animals.
Mads Laustsen, CEO of Bactolif:
“With this investment, Bactolife is able to boost our efforts in our technology platform, allowing us to reach our end customers faster and with inexpensive products that can benefit the many – potentially having an impact on millions of people’s lives worldwide.”
Bactolife’s deputy CEO, Sebastian Sderberg, continued: “We are grateful to the Bill & Melinda Gates Foundation for their support, and we are both honored and humbled by it. We appreciate the support of Novo Holdings and the Gates Foundation and see this as a strong endorsement of Bactolife’s ability to advance both human and animal health globally and make these products available in both developed and developing nations.”
Partner at Novo Seeds, part of Novo Holdings, Aleks Engel said:
“The Bill & Melinda Gates Foundation’s decision to invest in Bactolife is very exciting for Novo Holdings, and we believe that this demonstrates the enormous potential of Bactolife’s Binding ProteinTM platform to overcome and prevent antimicrobial resistance. The Bill & Melinda Gates Foundation is the right partner because of our shared interest in ensuring that everyone has access to effective medicines for common infectious diseases. We are enthusiastic about this study’s potential impact on resolving urgent global health issues.”
More about the company:
Bactolife is a developing company in the gut microbiome health sector in the food and feed industry. Innovative biological solutions are created by Bactolife using its patented Binding Protein technology, improving the gut microbiota and assisting in the difficult task of combating the emergence of antibiotic resistance and the overall burden of infectious diseases. Its patented platform use
Bactolife is a developing company in the gut microbiome health sector in the food and feed industry. Innovative biological solutions are created by Bactolife using its patented Binding Protein technology, improving the gut microbiota and assisting in the difficult task of combating the emergence of antibiotic resistance and the overall burden of infectious diseases. Its patented platform uses a method for choosing and creating binding proteins without directly affecting bacterial growth or killing them. Utilizing cutting-edge biomanufacturing techniques, binding proteins may be manufactured in vast quantities and are both stable and highly economical.
Most infections are now treated with antibiotics, many of which are either very expensive or propagate antibiotic-resistant germs. Bactolife has created ground-breaking Binding Proteins that can lower the risk of contracting gut infections at a reasonable cost to promote gut health for the benefit of both humans and animals. Binding Proteins can be formulated into food and feed items, making them simple to consume, thanks to the technology platform provided by Bactolife and the investment made by the Bill & Melinda Gates Foundation.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
